Loading provider…
Loading provider…
Rheumatology Physician in Potsdam, NY
NPI: 1457599532Primary Practice Location
CANTON-POTSDAM HOSPITAL
50 Leroy St, Potsdam, NY
Primary Employer
Canton - Potsdam Hospital
cphospital.org
HQ Phone
Get M.D. Eyal's Phone Numberphone_androidMobile
Get M.D. Eyal's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardWA State Medical License
NY State Medical License
Kaiser Permanente Northern California
Residency • Internal Medicine
2008 - 2009
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 213 | 319 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 114 | 135 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 84 | 94 |
| 4 | 20610Aspiration and/or injection of large joint or joint capsule | 26 | 29 |
| 5 | 99442Physician telephone patient service, 11-20 minutes of medical discussion | 24 | 28 |
A perspective on diet and gout.
Authors: Kedar, Eyal, Simkin, Peter A
Journal: Adv Chronic Kidney Dis
Novel Treatments for Airway Disease.
Authors: Katherine Cahill, Joshua Boyce, Praveen Akuthota
Journal: N Engl J Med
Abatacept for Treatment of Adults Hospitalized with Moderate or Severe Covid-19.
Authors: Phillip Smith, Jane Ohalloran, Christopher Palma, Phillip Smith, Samuel Bozzette, Daniel Benjamin, Tatyana Der, Thomas Patterson, Christopher Palma, William Powderly, Luis Parra-Rodriguez, Alfredo Mena Lora, Ave Lachiewicz
Journal: medRxiv
Publication Date: 2022-09-26
Lead Sponsor: Daniel Benjamin
Collaborators: National Center for Advancing Translational Sciences (NCATS), Biomedical Advanced Research and Development Authority
Intervention / Treatment: DRUG: Infliximab, DRUG: Remdesivir, DRUG: Abatacept, DRUG: cenicriviroc (closed to enrollment as of 3-Sep-2021)
Lead Sponsor: Eli Lilly and Company
Collaborators: Incyte Corporation
Intervention / Treatment: DRUG: Placebo, DRUG: Baricitinib
Lead Sponsor: Eli Lilly and Company
Collaborators: Incyte Corporation
Intervention / Treatment: DRUG: Placebo, DRUG: Baricitinib